4DMT Reports Q2 2026 Results, Extends Cash Runway to H2 2028
FDMT sits 90% above its 52-week low of $5.97.
Summary
4DMT reported Q2 2026 results with a $72.9M net loss and extended cash runway into H2 2028. Enrollment completed for 4FRONT-2, and DME Phase 3 initiation is expected in Q3 2026.
Key Events · Earnings and Guidance · FDMT
-
Q2 2026 Net Loss of $72.9M
Net loss widened from $54.7M in Q2 2025, driven by a 42% increase in R&D expenses to $68.3M for the 4D-150 Phase 3 trials.
-
Cash Runway Extended to H2 2028
Cash and marketable securities of $430.6M, plus expected Otsuka collaboration payments, are now expected to fund operations into the second half of 2028, versus the prior one-year runway.
-
4FRONT-2 Enrollment Completed
Enrollment for the global Phase 3 wet AMD trial completed in June 2026 with N>500 expected to be randomized; topline data expected in H2 2027.
-
DME Phase 3 Initiation Expected Q3 2026
Company plans to initiate a global Phase 3 trial for 4D-150 in diabetic macular edema in Q3 2026, with SPECTRA 2-year data expected in Q4 2026.
Analysis · FDMT · Life Sciences
4D Molecular Therapeutics reported a Q2 2026 net loss of $72.9 million, with R&D spending up 42% to $68.3 million. Cash and marketable securities of $430.6 million, combined with expected Otsuka payments, now fund operations into the second half of 2028 — a meaningful extension from the prior one-year runway. The company also completed enrollment in the 4FRONT-2 Phase 3 wet AMD trial and plans to initiate a DME Phase 3 in Q3 2026, with topline data from both 4FRONT trials expected in 2027.
At the time of this filing, FDMT was trading at $11.32 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $609M. The 52-week trading range was $5.97 to $14.00. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.